OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCL

February 17th 2016

Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.

Dr. Filosso on Future of Treating Patients With Lung NETs

February 16th 2016

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.

Dr. Martins on Patient Selection for Nivolumab in NSCLC

February 15th 2016

Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with nonâ€“small cell lung cancer (NSCLC).

Graham Dixon on Belinostat Plus CHOP in Patients With T-Cell Lymphoma

February 13th 2016

Graham Dixon, PhD, chief scientific officer, Onxeo, director, R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.

Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

February 12th 2016

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

Dr. Gershenson on Evolution of Targeted Therapies for Rare Gynecologic Malignancies

February 11th 2016

David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.

Dr. Ramalingam on Emerging Combination Regimens in NSCLC

February 10th 2016

Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with nonâ€“small cell lung cancer.

Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

February 9th 2016

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as a treatment for melanoma.

Dr. Eng on Emerging Agents for Treatment of Anal Cancer

February 8th 2016

Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.

Dr. Nguyen on ABL001 in Patients With CML

February 5th 2016

Marie Huong Nguyen, MD, assistant professor, Hematology and Oncology, University of Michigan Health System, discusses the safety and efficacy of ABL001 as a potential treatment for patients with chronic myeloid leukemia.

Dr. Khorana on Current Practice Patterns on Anticoagulant Treatments for Thrombosis

February 4th 2016

Alok A. Khorana, MD, professor of Medicine, Department of Hematology and Oncology, Cleveland Clinic, discusses a study that examined practice patterns and patient persistence on anticoagulant treatments for cancer-associated thrombosis.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Dr. Voorhees on Triplet Regimen in Multiple Myeloma

February 3rd 2016

Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.

Dr. Kirkwood on Annual Skin Screening for Melanoma

February 2nd 2016

John M. Kirkwood, MD, Usher Professor of Medicine, Dermatology & Translational Science, director, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, University of Pittsburgh, discusses a recent study that trained general practitioners and nurses to conduct annual skin examinations.

Dr. Maciejewski on Impact of Eltrombopag on Expansion of Clones in Refractory Aplastic Anemia

February 1st 2016

Jaroslaw P. Maciejewski, MD, PhD, chair, Department of Translational Hematology and Oncology Research, Cleveland Clinic, discusses the impact of eltrombopag on an expansion of clones with somatic mutations in patients with refractory aplastic anemia.

Dr. Hamilton on Prognostic Impact of Molecular Mutations in AML and MDS on HCT Outcomes

January 29th 2016

Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia and myelodysplastic syndromes on allogeneic hematopoietic cell transplant outcomes and the adverse impact of TET2 mutations.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.

Dr. Park on Alisertib in Myc-Overexpressing Lymphoma Cells

January 28th 2016

Steven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.

Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast Cancer

January 28th 2016

Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

Dr. Morris on Mechanism of Action for Radium-223

January 27th 2016

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.